Dreamm-4: evaluating safety and clinical activity of belantamab mafodotin (belamaf) in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (rrmm)

Dreamm-4: evaluating safety and clinical activity of belantamab mafodotin (belamaf) in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (rrmm)

Introduction: Single-agent belamaf (GSK2857916; BLENREP) has shown deep and durable responses and a manageable safety profile in patients with heavily pretreated RRMM (DREAMM-2, NCT03525678, Lancet Oncol 2020). Immune surveillance in patients with RRMM is often blunted through the PD-1/PDL-1 axis;...

Full description

Bibliographic Details
Main Authors: A. Medaglia, A.K. Nooka, M.V.M. Manteca, N. Bahlis, K. Weisel, A. Oriol, A.A. Alonso, A. Suvannasankha, B. Holkova, K. Luptakova, D. Fecteau, B.E. Kremer, M. Nichols, D. Williams, D.A Smith, R.C. Jewell, R. Montes de Oca, J. Opalinska, S. Trudel
Format: Article
Language:English
Published: PAGEPress Publications 2020-09-01
Series:Hematology Reports
Online Access:https://www.pagepress.org/journals/index.php/hr/article/view/8919

Internet

https://www.pagepress.org/journals/index.php/hr/article/view/8919

Similar Items